![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
First-Line Raltegravir (RAL) + Darunavir/Ritonavir (DRV/r) is Non-inferior to Tenofovir/Emtricitabine (TDF/FTC) + DRV/r: The NEAT 001/ANRS 143 Randomised Trial
|
|
|
Reported by Jules Levin
CROI 2014 March 3-6 Boston, MA
Franois Raffi1, Abdel G Babiker2, Laura Richert3, Jean-Michel Molina4,
Elizabeth C George2, Andrea Antinori5, Jose Arribas6, Stefano Vella7,
Genevieve Chne3, Anton L Pozniak8, and the NEAT001/ANRS143 Study Group
1University Hospital, Nantes, France; 2MRC Clinical Trials Unit at UCL, London, UK ; 3INSERM U897, Bordeaux, France; 4St Louis Hospital and University of Paris 7, France; 5INMI L Spallanzani, Rome, Italy; 6Hospital La Paz, IdiPAZ, Madrid, Spain; 7Istituto Superiore di Sanita, Rome, Italy ; 8Chelsea and Westminster Hospital, NHS Foundation Trust, London, UK
CROI webcast:
http://www.croiwebcasts.org/console/player/22172?mediaType=slideVideo&
![CROI1.gif](../images/030514/030514-8/CROI1.gif)
![CROI2.gif](../images/030514/030514-8/CROI2.gif)
![CROI3.gif](../images/030514/030514-8/CROI3.gif)
![CROI4.gif](../images/030514/030514-8/CROI4.gif)
![CROI5.gif](../images/030514/030514-8/CROI5.gif)
![CROI6.gif](../images/030514/030514-8/CROI6.gif)
![CROI7.gif](../images/030514/030514-8/CROI7.gif)
![CROI8.gif](../images/030514/030514-8/CROI8.gif)
![CROI9.gif](../images/030514/030514-8/CROI9.gif)
![CROI10.gif](../images/030514/030514-8/CROI10.gif)
![CROI11.gif](../images/030514/030514-8/CROI11.gif)
![CROI12.gif](../images/030514/030514-8/CROI12.gif)
![CROI13.gif](../images/030514/030514-8/CROI13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|